ALBUTEIN ALBUMIN (HUMAN) 10 g/50mL Injection, Solution, 100 mL
🆔 Identity & classification
Where does this data come from?
🏭 Manufacturer & labeler
Where does this data come from?
🩺 Clinical
Albumin (human) injection is used to treat low blood volume (hypovolemia) and low albumin levels in the blood (hypoalbuminemia) caused by bleeding, burns, major injuries or infections, malnutrition, major surgery, and other serious medical problems. It is also used during certain surgeries and medical treatments. Albumin (human) injection is in a class of medications called protein colloids. It works by keeping fluid from leaking out of blood vessels and helps to move important substances through the body.
Read the full MedlinePlus article ↗Patient education
Supplement & herbal interactions
Where does this data come from?
Ask a licensed pharmacist directly — free, answered by our team.
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 3EN9H0M2FX
A salt form of an amino acid derivative used as a solubilizer and stabilizer in liquid and injectable formulations. It helps keep active ingredients dissolved and protected from degradation during storage.
-
UNII 9XTM81VK2B
Sodium caprylate is a salt derived from caprylic acid, a naturally occurring fatty acid. In medicines, it acts as a preservative and antimicrobial agent to help prevent contamination and extend shelf life.
-
UNII 451W47IQ8X
Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.
-
UNII 059QF0KO0R
Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
4 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Albuked 10 g/50mL 76125-0791-10 | KEDRION | 1 vial | — | — | FDA listed | — |
| Plasbumin 10 g/50mL 13533-0691-20 | GRIFOLS | 1 vial | — | — | FDA listed | — |
| Human Albumin Grifols 10 g/50mL 61953-0001-01 | GRIFOLS | 1 vial | — | — | FDA listed | — |
| Albutein 10 g/50mLthis 68516-5215-08 | GRIFOLS | 100 ml | — | — | FDA listed | — |
Where does this data come from?
⏳ Availability & biosimilar status
Biologics have no small-molecule generics; biosimilar competition is tracked in the FDA Purple Book.
Where does this data come from?
📊 Medicare Part D spend CMS · PART D · 2025 (Q1-Q4)
🔬 Reported adverse events (FAERS)
Top reported reactions
Age at onset
Reporter sex
Serious outcomes
Where does this data come from?
📦 Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Status |
|---|---|---|---|
| 68516-5215-01 | 1 VIAL in 1 CARTON (68516-5215-1) / 50 mL in 1 VIAL (68516-5215-3) | 2022-03-01 | Active |
| 68516-5215-02 | 1 VIAL in 1 CARTON (68516-5215-2) / 100 mL in 1 VIAL (68516-5215-4) | 2022-03-01 | Active |
| 68516-5215-07 | 1 BAG in 1 CARTON (68516-5215-7) / 50 mL in 1 BAG (68516-5215-5) | 2021-11-08 | Active |
| 68516-5215-08 You're viewing this | 1 BAG in 1 CARTON (68516-5215-8) / 100 mL in 1 BAG (68516-5215-6) | 2021-11-08 | Active |
Pack size FAQ
What quantity is in NDC 68516-5215-08?
What is the difference between NDC 68516-5215-08 and NDC 68516-5215-07?
What NDC number is used to bill for this package of ALBUTEIN ALBUMIN (HUMAN) 10 g/50mL Injection, Solution?
🧭 About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |
Questions about this listing
Why is there no price listed?
Is the NDC printed on the package the same as the 11-digit billing NDC?
What do the three segments of this NDC mean?
Is this package still being marketed?
Does this product come in other package sizes?
Who lists this product with the FDA?
Where does this data come from?
📄 Full FDA label FDA SPL
🎯 Indications and Usage ▾
1. INDICATIONS AND USAGE Albumin (Human) U.S.P., Albutein ® 20% Solution is indicated: For treatment of hypovolemic shock. 1,2 As an adjunct in hemodialysis for patients undergoing long-term dialysis or for those patients who are fluid-overloaded and cannot tolerate substantial volumes of salt solution for therapy of shock or hypotension.
3 In cardiopulmonary bypass procedures; however, the optimum regimen of fluids has not been established. Conditions in which Albutein ® 20% MAY BE indicated: Adult respiratory distress syndrome (ARDS). 3,4 Major injury or surgery resulting in increased albumin loss or inadequate synthesis.
3,5 Acute nephrosis not responding to cyclophosphamide or steroid therapy. Steroid therapy may increase edema which may respond to combined therapy of albumin with a diuretic. 3 Acute liver failure or ascites where the therapeutic use is regulated by the individual circumstances.
3 Unless the pathologic condition responsible for hypoalbuminemia can be corrected, administration of albumin can afford only symptomatic relief. There is NO valid reason for the use of albumin as an intravenous nutrient. Albumin (Human) U.S.P., Albutein ® 20% Solution is indicated ( 1 ): For treatment of hypovolemic shock.
As an adjunct in hemodialysis for patients undergoing long-term dialysis or for those patients who are fluid-overloaded and cannot tolerate substantial volumes of salt solution for therapy of shock or hypotension. In cardiopulmonary bypass procedures; however, the optimum regimen of fluids has not been established. Conditions in which Albutein ® 20% MAY BE indicated: Adult respiratory distress syndrome (ARDS).
Major injury or surgery resulting in increased albumin loss or inadequate synthesis. Acute nephrosis not responding to cyclophosphamide or steroid therapy. Steroid therapy may increase edema which may respond to combined therapy of albumin with a diuretic.
Acute liver failure or ascites where the therapeutic use is regulated by the individual circumstances. Unless the pathologic condition responsible for hypoalbuminemia can be corrected, administration of albumin can afford only symptomatic relief. There is NO valid reason for the use of albumin as an intravenous nutrient.
⏱️ Dosage and Administration ▾
2. DOSAGE AND ADMINISTRATION Albutein ® 20% is administered intravenously. The total dosage will vary with the individual.
In adults, an initial infusion of 100 mL is suggested. Additional amounts may be administered as clinically indicated. In the treatment of the patient in shock with greatly reduced blood volume, Albutein ® 20% may be administered as rapidly as necessary in order to improve the clinical condition and restore normal blood volume.
This may be repeated in 15-30 minutes if the initial dose fails to prove adequate. In the patient with a slightly low or normal blood volume, the rate of administration should be 1 mL per minute. If dilution of Albutein ® 20% is clinically desirable, compatible diluents include sterile 0.9% Sodium Chloride solution or sterile 5% Dextrose in Water.
6 DIRECTIONS FOR USE: (50 mL and 100 mL) Albutein ® 20% is administered intravenously. The total dosage will vary with the individual. In adults, an initial infusion of 100 mL is suggested.
Additional amounts may be administered as clinically indicated. When an administration set is used ( 2.1 ) When an administration set is not used ( 2.2 )
2.1When an Administration Set is Used Flip off plastic cap on top of the vial and expose rubber stopper. Cleanse exposed rubber stopper with suitable germicidal solution, being sure to remove any excess. Observe aseptic technique and prepare sterile intravenous equipment as follows: Close clamp on administration set.
With bottle upright, squeeze drip chamber, thrust piercing pin straight through stopper center. Do not twist or angle. Immediately invert bottle, release drip chamber to automatically establish proper fluid level in drip chamber (half full).
Attach infusion set to administration set, open clamp and allow solution to expel air from tubing and needle, then close clamp. Make venipuncture and adjust flow. Discard all administration equipment after use.
Discard any unused contents.
2.2When an Administration Set is Not Used Flip off plastic cap on top of the vial and expose rubber stopper. Cleanse exposed rubber stopper with suitable germicidal solution, being sure to remove any excess. Observe aseptic technique and prepare sterile intravenous equipment as follows: Using aseptic technique, attach filter needle to a sterile disposable plastic syringe.
Insert filter needle into Albutein ® 20%. Aspirate Albutein ® 20% from the vial into the syringe. Remove and discard the filter needle from the syringe.
Attach desired size needle to syringe. Discard all administration equipment after use. Discard any unused contents.
💊 Dosage Forms and Strengths ▾
3. DOSAGE FORMS AND STRENGTHS Albutein ® 20% is a sterile, aqueous solution for single dose intravenous administration containing 20% human albumin (weight/volume). It is available in the following presentations: 10.0 g albumin/50 mL single dose vial.
20.0g albumin/100 mL single dose vial. Albutein ® 20% is a sterile, aqueous solution for single dose intravenous administration containing 20% human albumin (weight/volume), provided in the following presentations: ( 3 ) 10.0 g albumin/50 mL single dose vial 20.0 g albumin/100 mL single dose vial
⛔ Contraindications ▾
4. CONTRAINDICATIONS Albutein ® 20% is contraindicated in patients with severe anemia or cardiac failure in the presence of normal or increased intravascular volume. The use of Albutein ® 20% is contraindicated in patients with a history of allergic reactions to albumin. Patients with severe anemia or cardiac failure in the presence of normal or increased intravascular volume ( 4 ) Patients with a history of allergic reactions to albumin ( 4 )
⚠️ Warnings and Cautions ▾
5. WARNINGS AND PRECAUTIONS Risk of infectious agents ( 5.1 ) Patients with low cardiac reserve ( 5.2 )
5.1Warnings Following reports that there exists a risk of potentially fatal hemolysis and acute renal failure from the inappropriate use of Sterile Water for Injection as a diluent for Albumin (Human) 7 , if dilution is required, acceptable diluents include 0.9% Sodium Chloride or 5% Dextrose in Water. 6 Albutein ® 20% is made from pooled human plasma. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases, including a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD).
Although no cases of transmission of viral diseases or CJD have ever been identified for albumin, the risk of infectious agents cannot be totally eliminated. The physician should weigh the risks and benefits of the use of this product and should discuss these with the patient. Solutions of Albutein ® 20% should not be used if they appear turbid or if there is sediment in the bottle.
Do not begin administration more than 4 hours after the container has been entered. Discard unused portion.
5.2Precautions Albutein ® 20% should be administered with caution to patients with low cardiac reserve. Rapid infusion may cause vascular overload with resultant pulmonary edema. Patients should be closely monitored for signs of increased venous pressure.
A rapid rise in blood pressure following infusion necessitates careful observation of injured or postoperative patients to detect and treat severed blood vessels that may not have bled at a lower pressure. Patients with marked dehydration require administration of additional fluids. Albutein ® 20% may be administered with the usual dextrose and saline intravenous solutions.
However, certain solutions containing protein hydrolysates or alcohol must not be infused through the same administration set in conjunction with Albutein ® 20% since these combinations may cause the proteins to precipitate. See also PATIENT COUNSELING INFORMATION ( 17 ).
⚠️ Warnings ▾
5.1Warnings Following reports that there exists a risk of potentially fatal hemolysis and acute renal failure from the inappropriate use of Sterile Water for Injection as a diluent for Albumin (Human) 7 , if dilution is required, acceptable diluents include 0.9% Sodium Chloride or 5% Dextrose in Water. 6 Albutein ® 20% is made from pooled human plasma. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases, including a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD).
Although no cases of transmission of viral diseases or CJD have ever been identified for albumin, the risk of infectious agents cannot be totally eliminated. The physician should weigh the risks and benefits of the use of this product and should discuss these with the patient. Solutions of Albutein ® 20% should not be used if they appear turbid or if there is sediment in the bottle.
Do not begin administration more than 4 hours after the container has been entered. Discard unused portion.
🤒 Adverse Reactions ▾
6. ADVERSE REACTIONS The most common adverse reactions include fever and chills, rash, nausea, vomiting, tachycardia and hypotension. Should an adverse reaction occur, slow or stop the infusion for a short period of time which may result in the disappearance of the symptoms.
If administration has been stopped and the patient requires additional Albutein ® 20%, material from a different lot should be used. Albutein ® 20%, particularly if administered rapidly, may result in vascular overload with resultant pulmonary edema. To report SUSPECTED ADVERSE REACTIONS, contact Grifols Biologicals Inc. at 1-888-GRIFOLS (1-888-474-3657) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
The most common adverse reactions include fever and chills, rash, nausea, vomiting, tachycardia and hypotension ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Grifols Biologicals Inc. at 1-888-GRIFOLS (1-888-474-3657) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
👥 Use in Specific Populations ▾
8. USE IN SPECIFIC POPULATIONS Unknown whether can cause fetal harm or affect reproduction capacity ( 8.1 ) The pediatric use has not been clinically evaluated ( 8.4 )
8.1Pregnancy Pregnancy Category C. Animal reproduction studies have not been conducted with Albutein ® 20%. It is also not known whether Albutein ® 20% can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Albutein ® 20% should be given to a pregnant woman only if clearly needed.
8.4Pediatric Use Albutein ® 20% is indicated in conjunction with exchange transfusion in the treatment of neonatal hyperbilirubinemia. The pediatric use of Albutein ® 20% has not been clinically evaluated. The dosage will vary with the clinical state and body weight of the individual.
Typically, a dose one-quarter to one-half the adult dose may be administered, or dosage may be calculated on the basis of 0.6 to 1.0 gram per kilogram of body weight (3 to 5 mL of Albutein ® 20%). For jaundiced infants suffering from hemolytic disease of the newborn, the appropriate dose for binding of free serum bilirubin is 1 gram per kilogram of body weight which may be administered during the procedure. 8 The usual rate of administration in children should be one-quarter the adult rate.
Therefore, physicians should weigh the risks and benefits of the use of Albutein ® 20% in the pediatric population. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
🤰 Pregnancy ▾
8.1Pregnancy Pregnancy Category C. Animal reproduction studies have not been conducted with Albutein ® 20%. It is also not known whether Albutein ® 20% can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Albutein ® 20% should be given to a pregnant woman only if clearly needed.
🧒 Pediatric Use ▾
8.4Pediatric Use Albutein ® 20% is indicated in conjunction with exchange transfusion in the treatment of neonatal hyperbilirubinemia. The pediatric use of Albutein ® 20% has not been clinically evaluated. The dosage will vary with the clinical state and body weight of the individual.
Typically, a dose one-quarter to one-half the adult dose may be administered, or dosage may be calculated on the basis of 0.6 to 1.0 gram per kilogram of body weight (3 to 5 mL of Albutein ® 20%). For jaundiced infants suffering from hemolytic disease of the newborn, the appropriate dose for binding of free serum bilirubin is 1 gram per kilogram of body weight which may be administered during the procedure. 8 The usual rate of administration in children should be one-quarter the adult rate.
Therefore, physicians should weigh the risks and benefits of the use of Albutein ® 20% in the pediatric population. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
🧬 Clinical Pharmacology ▾
12. CLINICAL PHARMACOLOGY
12.1Mechanism of Action There are no known cases of viral hepatitis which have resulted from the administration of Albutein ® 20%. Albumin is a highly soluble, globular protein (MW 66,500), accounting for 70-80% of the colloid osmotic pressure of plasma. Therefore, it is important in regulating the osmotic pressure of plasma.
1,3 Albutein ® 20% supplies the oncotic equivalent of approximately 4 times its volume of human plasma. It will increase the circulating plasma volume by an amount approximately 2.5 times the volume infused within 15 minutes, if the recipient is adequately hydrated. 9 This extra fluid reduces hemoconcentration and decreases blood viscosity.
The degree and duration of volume expansion depend upon the initial blood volume. When treating patients with diminished blood volume, the effect of infused albumin may persist for many hours. The hemodilution lasts for a shorter time when albumin is administered to individuals with normal blood volume.
Albumin is also a transport protein and binds naturally occurring, therapeutic, and toxic materials in the circulation. 1 Albumin is distributed throughout the extracellular water and more than 60% of the body albumin pool is located in the extravascular fluid compartment. The total body albumin in a 70 kg man is approximately 320 g.
Albumin has a circulating life span of 15-20 days, with a turnover of approximately 15 g per day. 3
🧬 Mechanism of Action ▾
12.1Mechanism of Action There are no known cases of viral hepatitis which have resulted from the administration of Albutein ® 20%. Albumin is a highly soluble, globular protein (MW 66,500), accounting for 70-80% of the colloid osmotic pressure of plasma. Therefore, it is important in regulating the osmotic pressure of plasma.
1,3 Albutein ® 20% supplies the oncotic equivalent of approximately 4 times its volume of human plasma. It will increase the circulating plasma volume by an amount approximately 2.5 times the volume infused within 15 minutes, if the recipient is adequately hydrated. 9 This extra fluid reduces hemoconcentration and decreases blood viscosity.
The degree and duration of volume expansion depend upon the initial blood volume. When treating patients with diminished blood volume, the effect of infused albumin may persist for many hours. The hemodilution lasts for a shorter time when albumin is administered to individuals with normal blood volume.
Albumin is also a transport protein and binds naturally occurring, therapeutic, and toxic materials in the circulation. 1 Albumin is distributed throughout the extracellular water and more than 60% of the body albumin pool is located in the extravascular fluid compartment. The total body albumin in a 70 kg man is approximately 320 g.
Albumin has a circulating life span of 15-20 days, with a turnover of approximately 15 g per day. 3
📦 How Supplied / Storage and Handling ▾
16. HOW SUPPLIED/STORAGE AND HANDLING Albutein ® 20% is supplied as a sterile, aqueous solution for single dose intravenous administration containing 20% human albumin (weight/volume). It is available in the following vial sizes: 50 mL vial Albutein ® 20% (NDC 68516-5215-1). 100 mL vial Albutein ® 20% (NDC 68516-5215-2). Storage Albutein ® 20% is stable for three years provided that storage temperature does not exceed 30 °C. Protect from freezing.
📦 Storage and Handling ▾
Storage Albutein ® 20% is stable for three years provided that storage temperature does not exceed 30 °C. Protect from freezing.
📋 Description ▾
11. DESCRIPTION Albutein ® 20% is a sterile, aqueous solution for single dose intravenous administration containing 20% human albumin (weight/volume). Albutein ® 20% is prepared by a cold alcohol fractionation method from pooled human plasma obtained from venous blood.
The product is stabilized with 0.08 millimole sodium caprylate and 0.08 millimole sodium acetyltryptophanate per gram of albumin. Albutein ® 20% is osmotically equivalent to four times its volume of normal human plasma. Albutein ® 20% contains 130-160 milliequivalents of sodium ion per liter and has a pH of 7.0 ± 0.3.
The aluminum content of the solution is not more than 200 micrograms per liter during the shelf life of the product. The product contains no preservatives. Albutein ® 20% is heated at 60 °C for ten hours.
No positive assertion can be made, however, that this heat treatment completely destroys the causative agents of viral hepatitis.
💬 Information for Patients ▾
17. PATIENT COUNSELING INFORMATION The most common adverse reactions include fever and chills, rash, nausea, vomiting, tachycardia and hypotension. Depending on the severity of the reaction, patients should be advised to discontinue use of the product and contact their physician and/or seek immediate emergency care.
Albutein ® 20% should be administered with caution to patients with low cardiac reserve. Rapid infusion may cause vascular overload with resultant pulmonary edema. Patients should be closely monitored for signs of increased venous pressure.
A rapid rise in blood pressure following infusion necessitates careful observation of injured or postoperative patients to detect and treat severed blood vessels that may not have bled at a lower pressure. Patients with marked dehydration require administration of additional fluids. Albutein ® 20% may be administered with the usual dextrose and saline intravenous solutions.
However, solutions containing protein hydrolysates or alcohol must not be infused through the same administration set in conjunction with Albutein ® 20% since these combinations may cause the proteins to precipitate. See also WARNINGS AND PRECAUTIONS ( 5.2 ). Manufactured and Distributed by: Grifols Biologicals Inc.
Los Angeles, CA 90032, U.S.A. U. S.
License No. 1694 DATE OF REVISION: 07/2008 3028178